Navigation Links
AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain

s than placebo patients (p less than or equal to 0.0001 in both cases). In this study, Zenvia also demonstrated statistically significant improvements in a number of key secondary endpoints including the Pain Relief Ratings Scale and the Pain Intensity Ratings Scale. Although not statistically powered to detect differences in the secondary endpoint of Peripheral Neuropathy Quality of Life Scale Composite score, the DMQ 45 patients showed a greater improvement than placebo patients (p=0.05) and the DMQ 30 patients showed a greater improvement than placebo patients (p=0.08). Overall, the safety data from this study were consistent with data from previous studies. The most commonly reported adverse events were dizziness, nausea, diarrhea, fatigue and somnolence and were mild to moderate in nature. A higher number of patients in the DMQ 45 and DMQ 30 treatment groups (25.2% and 21.0%, respectively) discontinued due to an adverse event than compared to placebo (11.4%). There were no significant differences in serious adverse events with 7.6%, 4.8% and 4.1% reported in the DMQ 45, DMQ 30 and placebo groups, respectively and no deaths occurred during the study.

About Zenvia

Zenvia is a combination of two well-characterized compounds, the therapeutically active ingredient dextromethorphan, and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. This first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways, through pre-synaptic inhibition of glutamate release via sigma-1 receptor agonist activity, and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity. Zenvia is currently in development for the treatment of Involuntary Emotional Expression Disorder (IEED) and DPN pain.

In October 2006, the Company received an approvable letter for the treatment of Zenvia in IEED. To address safety concerns raised in the FDA's a
'"/>




Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:3/3/2015)... , March 3, 2015 The European ... defines and segments the concerned market in Europe ... non-invasive & minimally invasive cardiac output monitoring devices market in ... in 2014 and is estimated to grow to $89.8 million ... 2019. Browse through the TOC of European non-invasive ...
(Date:3/2/2015)... 2, 2015 Cure SMA recently announced a new ... Research (CALIBR). This funding is an extension of a spinal ... $700,000 Cure SMA grant to Dr. Peter G. Schultz ... of Small Molecules that Increase SMN2 Levels for ... neuron (SMN) protein is critical to the function of the ...
(Date:3/2/2015)... GLENWOOD, Ill. , March 2, 2015  Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... today announced it will release financial results for the ... Monday, March 9, 2015. The Company ... Tuesday, March 10, 2015 at 9:00 a.m. Central Time ...
Breaking Medicine Technology:European Non-Invasive & Minimally Invasive Cardiac Output Monitoring Devices Market is Expected to Reach $89.8 Million by 2019, at a CAGR of 4.2% from 2014 to 2019 2European Non-Invasive & Minimally Invasive Cardiac Output Monitoring Devices Market is Expected to Reach $89.8 Million by 2019, at a CAGR of 4.2% from 2014 to 2019 3Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 3Landauer, Inc. Announces Date and Time for Announcement of Fiscal First Quarter 2015 Results and Conference Call 2
... Genprex, Inc. announced today that it will be presenting at ... San Francisco.   Greg Heinlein , Chief Operating and Financial Officer, ... Forum , on October 25 starting at 11 a.m. PDT in ... be made available on the company,s website under the News & ...
... CINCINNATI, Oct. 20, 2011 Prasco Laboratories , announced ... Eli Lilly and Company (NYSE: LLY ... Tablets and ZYPREXA® ZYDIS (olanzapine) Orally Disintegrating Tablets, in the ... products upon the first ANDA entrant into the market.  Prasco ...
Cached Medicine Technology:Genprex Presenting at 10th Annual BIO Investor Forum 2Prasco® Selected as Eli Lilly and Company's Authorized Generics Partner 2
(Date:3/3/2015)... 03, 2015 Motion 5 ... Environment from Pixel Film Studios. , “inMotion3D Environment is ... into 360° viewing area inside Motion 5” said Christina ... the line between professional and amateur making this plugin ... turn their 2D HDRI images into 360° viewing area ...
(Date:3/3/2015)... Salt Lake City, UT (PRWEB) March 03, 2015 ... is an innovative, user-friendly website that focuses ... wilderness therapy, therapeutic boarding schools, and addiction treatment ... Additionally, all residential interventions on the site ... assessments, anxiety, ADHD, autism spectrum disorders, severe learning ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Formetco today ... billboard design. The FTX uses state-of-the-art technology to ... performance reliability, and owner satisfaction. An item of ... the exclusive Formetco 10 year LED Brightness Warranty. , ... to be a superior billboard among any other billboard ...
(Date:3/2/2015)... 02, 2015 Today at the ... in partnership with the California Healthcare Institute (CHI) ... presented an Assembly resolution recognizing Feb. 28, 2015 ... healthcare professionals caring for millions of Californians living ... nonprofit, public policy research organization, representing leading California ...
(Date:3/2/2015)... 02, 2015 Cutler Integrative Medicine a ... the root, gives cutting-edge tips to bring about self-renewal. ... renew the body by first cleaning house. According ... “We are all Toxic.” Between environmental toxins like heavy ... greatness, and our high stress levels, we all have ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled inMotion3D Environment Was Released Today from Pixel Film Studios Exclusively for Motion 5 2Health News:All Kinds of Therapy – New Website for Behavioral Health and Substance Abuse Treatment Launches Today 2Health News:Formetco Launches Innovative LED Billboard System 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 3Health News:Skin and Wellness Power Couple give Quick Tips to Self-Renewal for Spring 2
... Cornell University and Dartmouth University have explained the biological ... why people get sleepy at night and wake ... transfers energy from light to chemical reactions in cells, ... even some forms of cancer in humans. ,Circadian ...
... in a gene called FGFR2 could accelerate the development ... uterine cancer. Researchers at Washington University School of Medicine ... (TGen); the Wellcome Trust Sanger Institute, which is part ... Medicine reported the findings in the May 21, 2007, ...
... Taubman lost a good friend to amyotrophic lateral sclerosis ... disease or ALS. ,The memory of watching ... condition has never left Mr. Taubmans mind. And that memory ... of Michigan Medical School and beyond. ,Now, he ...
... Army hospital here has conducted an accident victim's multiple organ ... to three individuals. ,The retrievals were conducted ... and the organs were transplanted Thursday on two patients at ... ,Donor Ramesh Chand, 60, whose two sons serve ...
... the DNA by Watson and Crick the imperious role ... been widely acknowledged. Genes produce an array of proteins, ... individuals functioning or, may coerce other genes to perform ... that adequate research is carried out to understand the ...
... team of engineers, scientists and clinicians from the ... could play a role in heart failure ... ,Patients who have the disease may have narrowed, ... blood flow is blocked and tiny blood clots ...
Cached Medicine News:Health News:Circadian Clocks Triggered Chemical Reactions may Be Behind Jet Lag 2Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 2Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 3Health News:$5M Gift Will Attack Lou Gehrig's Disease 2Health News:$5M Gift Will Attack Lou Gehrig's Disease 3Health News:Army Hospital Conducts First Multiple Organ Retrieval and Transplantation 2Health News:Drink, Binge and the Genetic Link 2Health News:Drink, Binge and the Genetic Link 3Health News:Research may Yield Improved Treatment for Diseased Lungs 2
Substrate Plasma for Factor VIII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VIII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor XI Assay by STA© Analyzers. Freeze-dried human plasma lacking factor XI....
Enzyme Immunoassay of von Willebrand Factor Antigenby ELISA Method, 96 tests....
Colorimetric Assay of Plasminogen Activity by STA© Analyzers....
Medicine Products: